Literature DB >> 6307133

Pharmacokinetics of sulbactam in humans.

G Foulds, J P Stankewich, D C Marshall, M M O'Brien, S L Hayes, D J Weidler, F G McMahon.   

Abstract

Sulbactam, a new beta-lactamase inhibitor, has pharmacokinetic characteristics in humans similar to those of ampicillin and amoxicillin. Its half-life in humans is approximately 1 h. In a two-compartment pharmacokinetic model, the apparent volume of distribution for the central compartment is approximately 12 liters, and half of the dose is found in the central compartment in the postdistributive phase. Approximately 75% of a parenteral dose is excreted unchanged in urine. The coadministration of sulbactam with ampicillin, penicillin G, or cefoperazone has essentially no effect upon the kinetics of either the beta-lactam antibiotic or sulbactam.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6307133      PMCID: PMC184789          DOI: 10.1128/AAC.23.5.692

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  SODIUM AMPICILLIN: ABSORPTION AND EXCRETION OF INTRAMUSCULAR AND INTRAVENOUS DOSES IN NORMAL YOUNG MEN.

Authors:  T C EICKHOFF; J W KISLAK; M FINLAND
Journal:  Am J Med Sci       Date:  1965-02       Impact factor: 2.378

2.  Automated plate diffusion zone measurement and computerized data handling.

Authors:  R B Dardas; J H Perry; Z A Coles; C G Iwanicki
Journal:  Bull Parenter Drug Assoc       Date:  1973 Jul-Aug

3.  Comparative blood levels of hetacillin, ampicillin and penicillin G.

Authors:  S B Tuano; L D Johnson; J L Brodie; W M Kirby
Journal:  N Engl J Med       Date:  1966-09-22       Impact factor: 91.245

4.  Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration.

Authors:  R M Brown; R Wise; J M Andrews; J Hancox
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

5.  Evaluation of gas and other chromatographic separations of indolic methyl esters.

Authors:  C Grunwald; M Vendrell; B B Stowe
Journal:  Anal Biochem       Date:  1967-09       Impact factor: 3.365

6.  A sulfone beta-lactam compound which acts as a beta-lactamase inhibitor.

Authors:  N Aswapokee; H C Neu
Journal:  J Antibiot (Tokyo)       Date:  1978-12       Impact factor: 2.649

7.  Effect of probenecid on the excretion of ampicillin in human bile.

Authors:  J Kampmann; F Lindahl; J M Hansen; K Siersbaek-Nielsen
Journal:  Br J Pharmacol       Date:  1973-04       Impact factor: 8.739

8.  CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides.

Authors:  J A Retsema; A R English; A E Girard
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

9.  The influence of a new benzoic acid derivative on the metabolism of paraaminosalicylic acid (PAS) and penicillin.

Authors:  W P BOGER; J O BEATTY; F W PITTS; H F FLIPPIN
Journal:  Ann Intern Med       Date:  1950-07       Impact factor: 25.391

10.  Penicillanic acid sulfone: an unexpected isotope effect in the interaction of 6 alpha- and 6 beta-monodeuterio and of 6,6-dideuterio derivatives with RTEM beta-lactamase from Escherichia coli.

Authors:  D G Brenner; J R Knowles
Journal:  Biochemistry       Date:  1981-06-23       Impact factor: 3.162

View more
  39 in total

1.  Concentrations of ampicillin and sulbactam in serum and tissues of patients undergoing ENT surgery.

Authors:  A Wildfeuer; H Luckhaupt; M Springsklee
Journal:  Infection       Date:  1991 Jan-Feb       Impact factor: 3.553

2.  Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.

Authors:  R A Blum; R K Kohli; N J Harrison; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad-spectrum TEM-3 beta-lactamase.

Authors:  F Caron; L Gutmann; A Bure; B Pangon; J M Vallois; A Pechinot; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

4.  Multiple-dose pharmacokinetics and toleration of intravenously administered cefoperazone and sulbactam when given as single agents or in combination.

Authors:  D P Reitberg; T J Whall; M Chung; D Blickens; H Swarz; J Arnold
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

5.  High-pressure liquid chromatographic assay of sulbactam in plasma, urine, and tissue.

Authors:  R E Bawdon; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

6.  Penetration of ampicillin and sulbactam into human epididymis and testis.

Authors:  T Klotz; M Braun; A Wildfeuer; U Engelmann
Journal:  Infection       Date:  1996 Sep-Oct       Impact factor: 3.553

7.  Comparison of concentrations of sulbactam-ampicillin administered by bolus injections or bolus plus continuous infusion in tissues of patients undergoing colorectal surgery.

Authors:  C Martin; A Cotin; A Giraud; M Beccani-Argème; P Alliot; M N Mallet; M Argème
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 8.  Chemistry of newer antibiotics directed toward overcoming bacterial resistance.

Authors:  L A Mitscher
Journal:  Bull N Y Acad Med       Date:  1987-04

Review 9.  Beta-lactamase inhibitors from laboratory to clinic.

Authors:  K Bush
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

10.  Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.

Authors:  D P Reitberg; D A Marble; R W Schultz; T J Whall; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.